{"artifact":{"id":"paper-fig-88c46e91-48d0-4f1a-82f0-be0b1797f885-8","artifact_type":"paper_figure","entity_ids":"[]","title":"FIGURE 8: Network pharmacology and molecular docking analysis. (A) ZYSD active ingredient‐...","quality_score":0.5,"created_by":"paper_figures_pipeline","provenance_chain":"[{\"source\": \"paper\", \"paper_id\": \"88c46e91-48d0-4f1a-82f0-be0b1797f885\", \"relation\": \"extracted_from\"}]","content_hash":"d030eb8d2912a59c03d00b5c65dd5ed36924cd445a720a45cf5587192ad59261","metadata":{"doi":"10.1002/fsn3.71798","pmcid":"PMC13092805","_origin":{"url":"https://www.ebi.ac.uk/europepmc/articles/PMC13092805/bin/FSN3-14-e71798-g004.jpg","type":"external","tracked_at":"2026-04-27T06:18:10.473133"},"caption":"Network pharmacology and molecular docking analysis. (A) ZYSD active ingredient‐target network. (B) Venn diagram of active ingredients and disease targets. (C) The potential target protein interaction map of ZYSD, and the closer its color is to red, the more related targets interact with that target. (D) Cellular compound. (E) Biological process. (F) Molecular function. (G) KEGG enrichment analysis. (H) Molecular docking between liquiritin and AKT1. (I) Molecular docking between ginsenosides Rb3 and AKT1. (J) Molecular docking between salvianolic acid C and AKT1. (K) Molecular docking between glycyrrhetinic acid and AKT1. (L) Molecular docking between ginsenosides Rb3 and NRF2. (M) Molecular docking between epimedin A and NRF2. (N) Molecular docking between salvianolic acid C and NRF2. (O) Molecular docking between glycyrrhetinic acid and NRF2.","paper_id":"88c46e91-48d0-4f1a-82f0-be0b1797f885","image_url":"https://www.ebi.ac.uk/europepmc/articles/PMC13092805/bin/FSN3-14-e71798-g004.jpg","image_path":"","description":"","figure_label":"FIGURE 8","figure_number":8,"_schema_version":1,"source_strategy":"pmc_api","entities_mentioned":""},"created_at":"2026-04-26T23:18:10.473482-07:00","updated_at":"2026-04-26T23:18:10.473482-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"external","origin_url":"https://www.ebi.ac.uk/europepmc/articles/PMC13092805/bin/FSN3-14-e71798-g004.jpg","lifecycle_changed_at":"2026-04-26T23:18:10.473482-07:00","citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":null,"contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"20970417-7d92-4dbd-92b5-4c4d560dd690","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"paper_figures_pipeline"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[],"incoming_links":[],"current_artifact_id":"paper-fig-88c46e91-48d0-4f1a-82f0-be0b1797f885-8","is_canonical":true,"supersede_chain":["paper-fig-88c46e91-48d0-4f1a-82f0-be0b1797f885-8"]}